Rapamycin, an mTOR inhibitor, disrupts triglyceride metabolism in guinea pigs

Dimple Aggarwal, Maria Luz Fernandez, Ghada A. Soliman

Research output: Contribution to journalArticle

41 Citations (Scopus)

Abstract

This study was designed to define some of the mechanisms by which rapamycin (RAPA), an mTOR inhibitor, induces hypertriglyceridemia when used as an immunosuppressive or antiproliferative agent and to determine whether low doses result in less undesirable side effects. Thirty male guinea pigs (n = 10 per group) were randomly assigned to control (no RAPA), low-RAPA (0.08 mg/d), or high-RAPA (0.85 mg/d) treatment for 3 weeks. Rapamycin treatment resulted in more than a 2-fold increase in plasma triglycerides (TG) (P < .01), whereas no differences were observed in plasma cholesterol between RAPA and control groups. Low-RAPA treatment resulted in lower concentrations of cholesterol in the aorta (28.6%) and lower hepatic acyl-CoA cholesteryl acyltransferase activity compared to control and high-RAPA groups (P < .01). In addition, acyl-CoA cholesteryl acyltransferase activity was positively correlated with aortic cholesterol (r = 0.43, P < .05). In contrast, aortic TG concentrations were higher in RAPA-treated guinea pigs than in control (P < .01). Very low density lipoprotein and low-density lipoprotein particles isolated from guinea pigs treated with RAPA were larger in size and contained more TG molecules than particles from control animals. Interestingly, plasma free fatty acids and fasting plasma glucose were 65% and 72% higher in the high-RAPA group than in control (P < .01). Tumor necrosis factor-α concentrations in the aorta were 3.6- and 10.4-fold higher in the low-RAPA and high-RAPA groups than in control guinea pigs (P < .01). These results suggest that RAPA interferes with TG metabolism by altering the insulin signaling pathway, inducing increased secretion of very low density lipoprotein and promoting deposition of TG in the aorta. Low RAPA was found to decrease cholesterol accumulation in tissue (liver and aorta) compared to high RAPA, suggesting that lower doses could be less detrimental to transplant patients.

Original languageEnglish (US)
Pages (from-to)794-802
Number of pages9
JournalMetabolism: Clinical and Experimental
Volume55
Issue number6
DOIs
StatePublished - Jun 1 2006

Fingerprint

Sirolimus
Guinea Pigs
Triglycerides
Aorta
Cholesterol
Acyltransferases
Acyl Coenzyme A
VLDL Lipoproteins
Control Groups
Hypertriglyceridemia
Liver
Immunosuppressive Agents
LDL Lipoproteins
Nonesterified Fatty Acids

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism
  • Endocrinology

Cite this

Rapamycin, an mTOR inhibitor, disrupts triglyceride metabolism in guinea pigs. / Aggarwal, Dimple; Fernandez, Maria Luz; Soliman, Ghada A.

In: Metabolism: Clinical and Experimental, Vol. 55, No. 6, 01.06.2006, p. 794-802.

Research output: Contribution to journalArticle

Aggarwal, Dimple ; Fernandez, Maria Luz ; Soliman, Ghada A. / Rapamycin, an mTOR inhibitor, disrupts triglyceride metabolism in guinea pigs. In: Metabolism: Clinical and Experimental. 2006 ; Vol. 55, No. 6. pp. 794-802.
@article{5a1e3808bb6e462eb4c5b1d2b857ef3b,
title = "Rapamycin, an mTOR inhibitor, disrupts triglyceride metabolism in guinea pigs",
abstract = "This study was designed to define some of the mechanisms by which rapamycin (RAPA), an mTOR inhibitor, induces hypertriglyceridemia when used as an immunosuppressive or antiproliferative agent and to determine whether low doses result in less undesirable side effects. Thirty male guinea pigs (n = 10 per group) were randomly assigned to control (no RAPA), low-RAPA (0.08 mg/d), or high-RAPA (0.85 mg/d) treatment for 3 weeks. Rapamycin treatment resulted in more than a 2-fold increase in plasma triglycerides (TG) (P < .01), whereas no differences were observed in plasma cholesterol between RAPA and control groups. Low-RAPA treatment resulted in lower concentrations of cholesterol in the aorta (28.6{\%}) and lower hepatic acyl-CoA cholesteryl acyltransferase activity compared to control and high-RAPA groups (P < .01). In addition, acyl-CoA cholesteryl acyltransferase activity was positively correlated with aortic cholesterol (r = 0.43, P < .05). In contrast, aortic TG concentrations were higher in RAPA-treated guinea pigs than in control (P < .01). Very low density lipoprotein and low-density lipoprotein particles isolated from guinea pigs treated with RAPA were larger in size and contained more TG molecules than particles from control animals. Interestingly, plasma free fatty acids and fasting plasma glucose were 65{\%} and 72{\%} higher in the high-RAPA group than in control (P < .01). Tumor necrosis factor-α concentrations in the aorta were 3.6- and 10.4-fold higher in the low-RAPA and high-RAPA groups than in control guinea pigs (P < .01). These results suggest that RAPA interferes with TG metabolism by altering the insulin signaling pathway, inducing increased secretion of very low density lipoprotein and promoting deposition of TG in the aorta. Low RAPA was found to decrease cholesterol accumulation in tissue (liver and aorta) compared to high RAPA, suggesting that lower doses could be less detrimental to transplant patients.",
author = "Dimple Aggarwal and Fernandez, {Maria Luz} and Soliman, {Ghada A.}",
year = "2006",
month = "6",
day = "1",
doi = "10.1016/j.metabol.2006.01.017",
language = "English (US)",
volume = "55",
pages = "794--802",
journal = "Metabolism: Clinical and Experimental",
issn = "0026-0495",
publisher = "W.B. Saunders Ltd",
number = "6",

}

TY - JOUR

T1 - Rapamycin, an mTOR inhibitor, disrupts triglyceride metabolism in guinea pigs

AU - Aggarwal, Dimple

AU - Fernandez, Maria Luz

AU - Soliman, Ghada A.

PY - 2006/6/1

Y1 - 2006/6/1

N2 - This study was designed to define some of the mechanisms by which rapamycin (RAPA), an mTOR inhibitor, induces hypertriglyceridemia when used as an immunosuppressive or antiproliferative agent and to determine whether low doses result in less undesirable side effects. Thirty male guinea pigs (n = 10 per group) were randomly assigned to control (no RAPA), low-RAPA (0.08 mg/d), or high-RAPA (0.85 mg/d) treatment for 3 weeks. Rapamycin treatment resulted in more than a 2-fold increase in plasma triglycerides (TG) (P < .01), whereas no differences were observed in plasma cholesterol between RAPA and control groups. Low-RAPA treatment resulted in lower concentrations of cholesterol in the aorta (28.6%) and lower hepatic acyl-CoA cholesteryl acyltransferase activity compared to control and high-RAPA groups (P < .01). In addition, acyl-CoA cholesteryl acyltransferase activity was positively correlated with aortic cholesterol (r = 0.43, P < .05). In contrast, aortic TG concentrations were higher in RAPA-treated guinea pigs than in control (P < .01). Very low density lipoprotein and low-density lipoprotein particles isolated from guinea pigs treated with RAPA were larger in size and contained more TG molecules than particles from control animals. Interestingly, plasma free fatty acids and fasting plasma glucose were 65% and 72% higher in the high-RAPA group than in control (P < .01). Tumor necrosis factor-α concentrations in the aorta were 3.6- and 10.4-fold higher in the low-RAPA and high-RAPA groups than in control guinea pigs (P < .01). These results suggest that RAPA interferes with TG metabolism by altering the insulin signaling pathway, inducing increased secretion of very low density lipoprotein and promoting deposition of TG in the aorta. Low RAPA was found to decrease cholesterol accumulation in tissue (liver and aorta) compared to high RAPA, suggesting that lower doses could be less detrimental to transplant patients.

AB - This study was designed to define some of the mechanisms by which rapamycin (RAPA), an mTOR inhibitor, induces hypertriglyceridemia when used as an immunosuppressive or antiproliferative agent and to determine whether low doses result in less undesirable side effects. Thirty male guinea pigs (n = 10 per group) were randomly assigned to control (no RAPA), low-RAPA (0.08 mg/d), or high-RAPA (0.85 mg/d) treatment for 3 weeks. Rapamycin treatment resulted in more than a 2-fold increase in plasma triglycerides (TG) (P < .01), whereas no differences were observed in plasma cholesterol between RAPA and control groups. Low-RAPA treatment resulted in lower concentrations of cholesterol in the aorta (28.6%) and lower hepatic acyl-CoA cholesteryl acyltransferase activity compared to control and high-RAPA groups (P < .01). In addition, acyl-CoA cholesteryl acyltransferase activity was positively correlated with aortic cholesterol (r = 0.43, P < .05). In contrast, aortic TG concentrations were higher in RAPA-treated guinea pigs than in control (P < .01). Very low density lipoprotein and low-density lipoprotein particles isolated from guinea pigs treated with RAPA were larger in size and contained more TG molecules than particles from control animals. Interestingly, plasma free fatty acids and fasting plasma glucose were 65% and 72% higher in the high-RAPA group than in control (P < .01). Tumor necrosis factor-α concentrations in the aorta were 3.6- and 10.4-fold higher in the low-RAPA and high-RAPA groups than in control guinea pigs (P < .01). These results suggest that RAPA interferes with TG metabolism by altering the insulin signaling pathway, inducing increased secretion of very low density lipoprotein and promoting deposition of TG in the aorta. Low RAPA was found to decrease cholesterol accumulation in tissue (liver and aorta) compared to high RAPA, suggesting that lower doses could be less detrimental to transplant patients.

UR - http://www.scopus.com/inward/record.url?scp=33646140851&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33646140851&partnerID=8YFLogxK

U2 - 10.1016/j.metabol.2006.01.017

DO - 10.1016/j.metabol.2006.01.017

M3 - Article

C2 - 16713440

AN - SCOPUS:33646140851

VL - 55

SP - 794

EP - 802

JO - Metabolism: Clinical and Experimental

JF - Metabolism: Clinical and Experimental

SN - 0026-0495

IS - 6

ER -